Labcorp (LH) and OPKO Health, Inc. announced the completion of Labcorp's acquisition of select BioReference Health assets focused on oncology and oncology-related clinical testing across the U.S.
The transaction, valued at up to $225 million, includes $192.5 million paid at closing and up to $32.5 million in potential earnouts based on performance.
Labcorp President and COO Mark Schroeder said the acquisition expands access to Labcorp's high-quality laboratory services and strengthens its oncology capabilities, reinforcing its commitment to advancing cancer care. OPKO Chairman and CEO Dr. Phillip Frost highlighted that the transaction allows BioReference Health to focus on its core clinical testing operations and 4Kscore® Test franchise, which generated around $300 million in 2024 revenue. OPKO intends to use part of the proceeds to support its expanded share repurchase authorization.
Monday, LH closed at $275.40, down 0.92%, and is trading flat after hours on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.